Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A.
Korotych O, et al. Among authors: hovhannesyan a.
Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00228-7. doi: 10.1016/S1473-3099(24)00228-7. Online ahead of print.
Lancet Infect Dis. 2024.
PMID: 38880112
Free article.